Minor Cannabinoids Show Early Promise in Skin-Disease Research
A 2023 synthetic review published in Molecules examined whether lesser-known cannabinoids could eventually contribute to treatments for conditions such as acne, psoriasis, atopic dermatitis and pruritus. The authors, Emilia Kwiecień of the Medical University of Lublin and A-Sense chemistry lab and Dorota Kowalczuk of the Medical University of Lublin, analyzed findings from the existing scientific literature rather than conducting a new clinical trial.
The review covered compounds including cannabidivarin (CBDV), cannabidiforol (CBDP), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinol (CBN), cannabimovone (CBM) and cannabielsoin (CBE). Across the studies examined, these minor cannabinoids displayed potentially useful anti-inflammatory, analgesic, antimicrobial, antioxidant and anti-itch properties.
Much of the evidence, however, came from laboratory experiments and animal studies. Some research involving skin cells and sebocytes—cells that produce sebum—suggested that cannabinoids may influence inflammation, lipid production and immune signaling. Those mechanisms are relevant to acne, eczema and psoriasis, but laboratory activity does not establish that a cannabinoid-based product will safely or effectively treat patients.
THCV received particular attention for its possible effects on acne. Experimental research suggests it may reduce sebum production while also showing anti-inflammatory and antibacterial activity. CBC and CBDV were likewise identified as compounds of interest because of their reported anti-inflammatory and antioxidant effects. The review discussed CBDV in connection with inflammatory symptoms such as redness and itching, including those associated with atopic dermatitis.
The authors also highlighted the more limited evidence surrounding CBM and CBE. CBM has been investigated for activity involving PPAR-gamma, a receptor involved in inflammation and metabolism, while CBE has shown anti-inflammatory effects in experimental models. These findings may help guide future research, but they are not evidence that either compound is ready for routine dermatological treatment.
The proposed effects are consistent with the role of the skin’s endocannabinoid system, a network of receptors, naturally occurring signaling molecules and enzymes involved in processes including immune response, cell growth, differentiation and survival. Researchers have suggested that modulating this system could affect inflammation, pain, itching, barrier function and sebum production. The review also described topical cannabinoids as a possible area of research in skin aging, although claims about preventing or reversing photoaging remain preliminary.
Skin conditions discussed in the review affect large populations. The National Psoriasis Foundation reports that more than 8 million Americans have psoriasis. Their prevalence helps explain the interest in new therapies, particularly for people whose symptoms are not adequately controlled by existing treatments. It does not, by itself, demonstrate that cannabinoids are an effective alternative.
Important questions remain about dosage, absorption through the skin, long-term safety, drug interactions, manufacturing quality and the differences between purified cannabinoids and complex cannabis extracts. In the United States, the Food and Drug Administration cautions that unapproved CBD products have not been evaluated for effectiveness, appropriate dosing, interactions or safety. Products marketed for skin conditions may also vary substantially in cannabinoid concentration and purity.
The review therefore supports further investigation, not a conclusion that minor cannabinoids are established treatments for dermatological disease. Well-designed human trials will be needed to determine which compounds, formulations and delivery methods—if any—provide meaningful benefits. Until that evidence is available, people with persistent acne, eczema, psoriasis or severe itching should rely on evaluation and treatment from a qualified health professional rather than replacing proven care with an unapproved cannabinoid product.
